Cardiogen is another of the short "peptide bioregulators", marketed in a
cardiovascular context. The same evidence caveats that apply to the whole
bioregulator family apply here.
Chemical identity & structure.
Cardiogen is a synthetic short peptide — described in the bioregulator
literature as a tripeptide/tetrapeptide-class compound — and is one of the
tissue-targeted "peptide bioregulators" from the same Russian research program
as Pinealon, Vesugen, and Epithalon.
Mechanism of action.
The proposed mechanism is the family-wide bioregulator hypothesis: that the
short peptide interacts with DNA and modulates gene expression in a
tissue-associated manner — for Cardiogen, the claimed association is cardiac
and vascular tissue, with reported support for cardiac-cell function and repair
processes. This is a hypothesis from a specific research program; no
independently established receptor mechanism underlies the marketing.
Key research findings.
Reported findings, from that program, describe effects on cardiac-tissue cell
function and age-related cardiac markers in laboratory and animal models.
The research / citation base.
The Cardiogen literature is, like the rest of the bioregulator family,
**predominantly from a single Russian research program with limited independent
replication. Cardiogen is not approved** by the FDA or EMA. The marketed
cardiovascular claims are not supported by independent, Western-standard
clinical evidence.
No human clinical trial has established administration parameters for Cardiogen; VialTalk does
not provide community-sourced dosing.
Quality & sourcing notes.
A batch-specific COA with mass-spectrometry identity and HPLC purity is the
minimum bar. As with the other bioregulators, the evidence base — not purity —
is the real limitation.
*Research-use note: Educational summary of published research. Cardiogen is not
an approved drug and its evidence base is limited; this is research context only
and not medical advice.*